Treatment Advances in Waldenstrom Macroglobulinemia With Morie Gertz, MD, MACP

Oncology Data Advisor™ · Treatment Advances in Waldenstrom Macroglobulinemia Waldenstrom macroglobulinemia (WM) is a rare cancer of B lymphocytes associated with lymphoplasmacytic bone marrow infiltration and the presence of serum monoclonal immunoglobulin M (IgM) (LLS, 2021). Often considered a disease occurring in older adults, this malignancy accounts for between 1% and 2% of non-Hodgkin lymphomas (Dimopoulos & Kastritis, 2019; ACS, 2018).&n...

Continue reading

Updates in Mantle Cell Lymphoma With John Leonard, MD

Oncology Data Advisor™ · Updates in Mantle Cell Lymphoma Mantle cell lymphoma (MCL) is an aggressive variant of B-cell non-Hodgkin lymphoma that comprises approximately 5% of all lymphomas. Compared with patients who have other aggressive lymphomas, patients with MCL often do not respond as well to treatment (ACS, 2019).Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall sur...

Continue reading

Improving Outcomes in Hodgkin Lymphoma With Louis Diehl, MD

Oncology Data Advisor™ · Improving Outcomes in Hodgkin Lymphoma Hodgkin lymphoma (HL) is a rare malignancy of the lymph nodes and lymphatic system, with about 8,830 new cases diagnosed each year in the United States (Siegel et al, 2021). While the advent of novel therapies is leading to significantly improved outcomes, HL treatment continues to be associated with an increased risk for secondary cancers and cardiovascular disease (NCCN, 2021; Kreissl et al, 2020). In order to mi...

Continue reading

Therapy of B-Cell Acute Lymphoblastic Leukemia, An Evolving Landscape: Amir Fathi, MD

Oncology Data Advisor™ · Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells throughout the bone marrow and blood (Ranathunga et al, 2020). Although survival has improved in recent years due to considerable advances in treatment, the rate of relapse remains high (ASCO, 2021; Samra et al, 2020). One reason for this is that older patients are o...

Continue reading

i3 Health and Oncology Data Advisor Announce ODACon 2022, a Rare Hematologic Malignancies Symposium

ROCHELLE PARK, NJ—January 12, 2022 – i3 Health and Oncology Data Advisor have announced that ODACon, a Rare Hematologic Malignancies Symposium, will be held on January 29, 2022. This 1-day virtual conference features 5 exclusive sessions on emerging data in hematologic malignancies, including acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL), mantle cell lymphoma (MCL), myelodysplastic syndromes (MDS), and Waldenstrom macroglobulinemia (WM), all presented by expert faculty. Attendees can...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.